[Differentiated approaches to the treatment of chronic pancreatitis patients with metabolic syndrome].
OBJECTIVE
study and evaluation of clinical efficacy of combined use of Creon and Tricor in chronic pancreatitis (CP) accompanied by metabolic syndrome (MS).


METHODS
We observed 60 patients with CP accompanied by MS, of whom 30 patients received standard therapy complex CPs (comparison group), 30--received Creon (microspheres of pancreatin) and Tricor (fenofibrate) in the combined treatment (observation group). In assessing the effectiveness of therapies used in clinical and advanced laboratory and instrumental studies.


RESULTS
In the course of treatment in patients with the observation group occurred faster clinical improvement, improved lipid, carbohydrate and purine exchange and decreased insulin resistance.


CONCLUSIONS
The combined use of Creon and Tricor is pathogenetically substantiated and clinically effective in the CP accompanied by MS.
Ia M
IaM
Vakhrushev
A A
AA
Volkova
D000328:Adult; D000368:Aged; D050260:Carbohydrate Metabolism / Q000187:drug effects; D004359:Drug Therapy, Combination; D005260:Female; D011345:Fenofibrate / Q000008:administration & dosage*; D005765:Gastrointestinal Agents / Q000008:administration & dosage*; D006801:Humans; D000960:Hypolipidemic Agents; D050356:Lipid Metabolism / Q000187:drug effects; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D008875:Middle Aged; D050500:Pancreatitis, Chronic / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D020799:Pancrelipase / Q000008:administration & dosage*; D011687:Purines / Q000378:metabolism
D005765:Gastrointestinal Agents; D000960:Hypolipidemic Agents; D011687:Purines; D020799:Pancrelipase; D011345:Fenofibrate